NCT06898333 Implementation and Effectiveness of the BJC-Pink and Pearl Project on Lung Cancer Screening
| NCT ID | NCT06898333 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Washington University School of Medicine |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 279 participants |
| Start Date | 2025-05-08 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 279 participants in total. It began in 2025-05-08 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators proposal is ripe for executing as the investigators seek to leverage this "natural experiment" initiated by the BJC health system to evaluate the effectiveness of the Pink \& Pearl Campaign as an implementation strategy to promote lung cancer screening (LCS) uptake among LCS-eligible women undergoing mammography at BJC West County. This evaluation is grounded in the Integrated Screening Action Model that depicts individual- and environmental-level influences on the screening behavior process. Using an explanatory sequential mixed methods design, which combines both quantitative and qualitative approaches, the research questions and specific aims for this proposal are to: a) evaluate the baseline prevalence of LCS among LCS-eligible women; b) assess whether the Pink \& Pearl Campaign increases referrals and uptake/ completion of LCS among LCS-eligible women undergoing screening mammography; and c) evaluate individual and environmental factors influencing LCS uptake, and implementation outcomes of the campaign. These implementation outcomes will help identify whether the campaign was put in place successfully or not. This proposal will inform strategies for integrating cancer screening programs to improve poorly performing programs like LCS.
Eligibility Criteria
Inclusion Criteria for Participants: * Undergoing screening mammography * Between the ages of 50-80 years (inclusive) * Reporting a 20 pack-year equivalent of either current smoking history or have quit in the past 15 years * Can speak and understand English * Ability to understand willingness to provide informed consent. Exclusion Criteria for Participants: * Diagnosed with a serious health problem that will likely limit life expectancy (such as previous history of lung cancer, symptoms of lung cancer such as hemoptysis or unexplained weight loss of more than 6.8 kg (15 lb) in the previous year) * Subjects with symptoms of lung cancer should get a diagnostic CT scan * Unable or unwilling to get treatment if lung cancer is found Eligibility Criteria for Providers: * Older than 20 years of age
Contact & Investigator
Beryne Odeny, M.D., MPH, Ph.D.
PRINCIPAL INVESTIGATOR
Washington University School of Medicine
Frequently Asked Questions
Who can join the NCT06898333 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06898333 currently recruiting?
Yes, NCT06898333 is actively recruiting participants. Contact the research team at beryne@wustl.edu for enrollment information.
Where is the NCT06898333 trial being conducted?
This trial is being conducted at Creve Coeur, United States.
Who is sponsoring the NCT06898333 clinical trial?
NCT06898333 is sponsored by Washington University School of Medicine. The principal investigator is Beryne Odeny, M.D., MPH, Ph.D. at Washington University School of Medicine. The trial plans to enroll 279 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.